CD38 and plasma cell myeloma: In the acidic and hypoxic environment of the bone marrow niche, the CD38-ENPP1-CD73-mediated eADO pathway is more effective than the canonical pathway, which accounts for the observed antitumor effects of CD38 inhibition in myeloma [41].